` BIO (Biome Australia Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

B
BIO
vs
S
S&P/ASX 300

Over the past 12 months, BIO has underperformed S&P/ASX 300, delivering a return of -19% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
BIO vs S&P/ASX 300

Loading
BIO
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BIO vs S&P/ASX 300

Loading
BIO
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
BIO vs S&P/ASX 300

Loading
BIO
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Biome Australia Ltd vs Peers

S&P/ASX 300
BIO
OR
ULVR
HINDUNILVR
HLN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Biome Australia Ltd
Glance View

Market Cap
91.6m AUD
Industry
Consumer products

Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.

BIO Intrinsic Value
0.607 AUD
Undervaluation 32%
Intrinsic Value
Price
B
Back to Top